NEW YORK--(BUSINESS WIRE)--June 26, 2006--OSI Pharmaceuticals, Inc. (NASDAQ: OSIP - News) and Pfizer Inc. (NYSE: PFE - News) today announced the initiation of LEVEL (EvaLuation of Efficacy and safety in maintaining Visual acuity with sEquential treatment of neovascuLar AMD), a Phase IV trial that will explore the safety and efficacy of Macugen® (pegaptanib sodium injection) as a maintenance therapy for patients who have received prior neovascular AMD treatment and experienced improvement in macular disease. The 54-week trial, comprising up to 1000 patients at 100 sites across the country, is scheduled to enroll its first patient today.
